The Drug Court Scandal Morris B
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clandestine Drug Lab General Cleanup Guidance
Clandestine Drug Lab General Cleanup Guidance DIVISION OF ENVIRONMENTAL HEALTH i Minnesota Department of Health (MDH) Division of Environmental Health Minnesota Pollution Control Agency (MPCA) Clandestine Drug Lab General Cleanup Guidance September 2010 VERSION, Clarification to Table 1 March 2013 FOR MORE INFORMATION, CONTACT: MINNESOTA DEPARTMENT OF HEALTH DIVISION OF ENVIRONMENTAL HEALTH PO BOX 64975 ST. PAUL, MN 55164-0975 TEL: 651-201-4899 TOLL FREE: 888-657-3908 FAX: 651-201-4606 TDD: 651-201-5797 TO REQUEST THIS DOCUMENT IN ANOTHER FORMAT, SUCH AS LARGE PRINT, BRAILLE OR CASSETTE TAPE, CALL 651-201-4911; TDD 651-201-5797 OR TOLL-FREE THROUGH THE MN RELAY SERVICE, 1-800-627-3529.TABLE OF CONTENT ii TABLE OF CONTENTS Clandestine Drug Lab .................................................................................................................. i General Cleanup ..........................................................................................................................i Guidance ..................................................................................................................................i TABLE OF CONTENTS ............................................................................................................. iii ACKNOWLEDGEMENTS ........................................................................................................... v ACKNOWLEDGEMENTS ........................................................................................................... v I. INTRODUCTION .................................................................................................................. -
Supporting the Drug Court Process: What You Need to Know For
U.S. Department of Justice Office of Justice Programs Bureau of Justice Assistance Supporting the Drug Court Process:What You Need To Know for Effective Decisionmaking MONOGRAPHand Program Evaluation F EBRUARY 2003 SEARCH, The National Consortium for Justice Information and Statistics U.S. Department of Justice Office of Justice Programs 810 Seventh Street NW. Washington, DC 20531 John Ashcroft Attorney General Deborah J. Daniels Assistant Attorney General Richard R. Nedelkoff Director, Bureau of Justice Assistance Office of Justice Programs Home Page www.ojp.usdoj.gov Bureau of Justice Assistance Home Page www.ojp.usdoj.gov/BJA NCJ 197259 This document was prepared by SEARCH,The National Consortium for Justice Information and Statistics, under the Drug Court Training and Technical Assistance Program, under grant number 98–MU–VX–K017, awarded by the Office of Justice Programs, U.S. Department of Justice. The opinions, findings, and conclusions or recommendations expressed in this document are those of the authors and do not necessarily represent the official position or policies of the U.S. Department of Justice. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, and the Office for Victims of Crime. Notice n November 2002, the Bureau of Justice Assistance I Bureau of Justice 810 Seventh Street NW. Assistance (BJA) Washington, DC 20531 assumed responsibility Telephone: (202) 616–5001 for administering the Drug Court Grant Fax: (202) 514–6452 Program and the Drug Court Training and E-mail: [email protected] Technical Assistance Program. -
2008 Idaho Felony Drug Court Outcome Evaluation Report
An Examination of Idaho’s Felony Drug Courts: Findings and Recommendations FINAL REPORT Shelley Johnson Listwan, Ph.D. Institute for the Study and Prevention of Violence Department of Justice Studies Kent State University James Borowiak, M.A. Department of Justice Studies Kent State University & Edward J. Latessa, Ph.D. Center for Criminal Justice Research Division of Criminal Justice University of Cincinnati August 2008 ______________________________________________ This report was supported through a grant from the Idaho Supreme Court & the Substance Abuse and Mental Health Services Administration (CFDA 93.243). Views expressed are those of the authors and do not necessarily reflect the views of either funding agency. Table of Contents Acknowledgements………………………………………………………………………………3 List of Exhibits…………………………………………………………………………………...4 Section I. Overview………………...………………………………………………………10 Section II. Organizational Issues & Needs ………………………………………………..14 Methodology…………………………………………………………………….14 Sample…………………………………………………………………………...14 Court Descriptions……………………………………………………………...16 Results…………………………………………………………………………...23 Summary………………………………………………………………………...39 Section III. Statewide Outcome Evaluation Results……………………………………….41 Methodology…………………………………………………………………….41 Sample…………………………………………………………………………...41 Measures………………………………………………………………………...45 Analysis………………………………………………………………………….47 Results…………………………………………………………………………...47 Summary………………………………………………………………………..74 Section IV. GRPA Data Summary………………………………………………………….77 Methodology…………………………………………………………………….78 -
Exposures Associated with Clandestine Methamphetamine Drug Laboratories in Australia
Rev Environ Health 2016; 31(3): 329–352 Jackie Wright*, John Edwards and Stewart Walker Exposures associated with clandestine methamphetamine drug laboratories in Australia DOI 10.1515/reveh-2016-0017 Received April 20, 2016; accepted June 7, 2016; previously published Introduction online July 18, 2016 Illicit drugs such as amphetamine-type stimulants (ATS) Abstract: The clandestine manufacture of methamphet- (1) are manufactured in Australia within clandestine amine in residential homes may represent significant laboratories that range from crude, makeshift operations hazards and exposures not only to those involved in the using simple processes to sophisticated operations. These manufacture of the drugs but also to others living in the laboratories use a range of chemical precursors to manu- home (including children), neighbours and first respond- facture or “cook” ATS that include methylamphetamine, ers to the premises. These hazards are associated with more commonly referred to as methamphetamine (“ice”) the nature and improper storage and use of precursor and 3,4-methylenedioxymethamphetamine (MDMA or chemicals, intermediate chemicals and wastes, gases and “ecstasy”). In Australia the primary ATS manufactured methamphetamine residues generated during manufac- in clandestine drug laboratories is methamphetamine ture and the drugs themselves. Many of these compounds (2), which is the primary focus of this review. Clandes- are persistent and result in exposures inside a home not tine laboratories are commonly located within residential only during manufacture but after the laboratory has been homes, units, hotel rooms, backyard sheds and cars, with seized or removed. Hence new occupants of buildings for- increasing numbers detected in Australia each year (744 merly used to manufacture methamphetamine may be laboratories detected in 2013–2014) (2). -
Western Judicial Circuit Felony Drug Court
Western Judicial Circuit Felony Drug Court (Athens-Clarke and Oconee Counties) PARTICIPANT HANDBOOK This handbook belongs to: 325 E. Washington Street, Suite 210 Athens, Georgia 30601 (706) 208-7078 (706) 613-3179 (fax) Table of Contents Welcome 3 Overview 4-5 Confidentiality 5 Treatment 5 Program Phases 6-10 Commencement 11 Program Rules 12-14 Program Fees 15 The Drug Court Team 15 Staffings 15 Court Appearances 16 Incentives 17 Sanctions and Treatment Responses 17 Termination 18 Drug/Chemical Testing 19 Prohibited Drugs/Permitted Medications 20-27 Travel/Leave Requests 27 Compliance & Home Visits/Job Checks, Searches 28 Search Requirements 28 Commencement Ceremony 29 Conclusion 29 Important Phone Numbers 30 Community Resources 31 Attachment I: Random Drug Screen Policy Attachment II: Urine Abstinence Testing/Incidental Alcohol Exposure Contract (original signed copy on file with Felony Drug Court) Attachment III: Emergency On-call Telephone Policy Attachment IV: Felony Drug Court Contract 2 Welcome to the Western Judicial Circuit Felony Drug Court! This Handbook was designed to answer your questions and provide specific information about what you must do in order to successfully complete the requirements of the Western Judicial Circuit Felony Drug Court Program. As a participant, you are expected to follow the instructions found in this Handbook, as well as the instructions of the Felony Drug Court Judge, Staff, and Treatment Provider. You will also be expected to comply with the treatment plan developed for you by your Treatment Provider. This handbook is not exhaustive and there is no possible way to make it complete and detailed to answer every question or situation that arises. -
Retrospective Evaluation of Drug Courts in Clark County (Las Vegas) and Multnomah County (Portland)
The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: From Whether to How Drug Courts Work: Retrospective Evaluation of Drug Courts in Clark County (Las Vegas) and Multnomah County (Portland) Author(s): John S. Goldkamp ; Michael D. White ; Jennifer B. Robinson Document No.: 194124 Date Received: 05/05/2002 Award Number: 98-DC-VX-K001 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. R CRIME AND JUSTICE RESEARCHINSTITUTE .---- PROPERTY OF National Criminal Justice Reference Service (NCJRS) Box 6000 Rockville, MD 20849-6000 From Whether to How Drug Courts Work: Retrospective Evaluation of Drug Courts in , Clark County (Las Vegas) and Multnomah County (Portland) Phase II Report,fiorn the National Evaluation of Drug Courts (I) Johi S. Goldkamp Temple University Michael D. White University of North Florida Jennifer B. Robinson University of Ottawa c Approved By: Bate: The researc scribed in this report was supported by grant #98-DC-VX-K001 from the National Institute of Justice, United States Department of Justice. The points of view expressed in the document do not represent the official positions of the National Institute of Justice, the local justice agencies in Multnomah County and Clark County, nor the Federal Government. -
DRUG COURT REVIEW Winter 2019
DRUG COURT REVIEW Winter 2019 Rural Treatment Court Programs EDITOR IN CHIEF Julie Marie Baldwin, American University ASSOCIATE EDITORS Leola A. Abraham, American University John M. Eassey, American University EDITORIAL SUPPORT Steve Collins, American University Zephi Francis, American University Preeti P. Menon, American University ADVISORY COMMITTEE Jon D. Berg, Substance Abuse and Mental Health Services Administration Jerry Gardner, Tribal Law and Policy Institute Peggy Fulton Hora, Justice Speakers Institute Preeti Menon, American University Carrie F. Mulford, National Institute on Drug Abuse Roger H. Peters, University of South Florida Noreen Plumage, South Dakota State Court Administrators Office Annie Schachar, Center for Court Innovation Faye S. Taxman, George Mason University Gregory D. Torain, US Department of Justice EDITORIAL OFFICE Justice Programs Office American University 4801 Massachusetts Ave NW, Suite 508 Washington, DC 20016 This publication was supported by Grant No. 2016-DC-BX-K008 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Department of Justice’s Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office of Victims of Crime, and the SMART Office. Points of view or opinions in this document are those of the authors and do not necessarily represent the official position or policies of the US Department of Justice. Drug Court Review Winter 2019 3 Introduction to the Issue on Rural 4 - 7 Treatment Court Programs John M. Eassey The Effect of Disproportionate 8 - 25 Sanctioning on Client Noncompliance Jamie C. Vaske Treatment Needs and Gender 26 - 49 Differences Among Clients Entering a Rural Drug Treatment Court with a Co-occurring Disorder Paige M. -
Synergistic Use of Hyperspectral UV-Visible OMI and Broadband Meteorological Imager MODIS Data for a Merged Aerosol Product
remote sensing Article Synergistic Use of Hyperspectral UV-Visible OMI and Broadband Meteorological Imager MODIS Data for a Merged Aerosol Product Sujung Go 1,2 , Jhoon Kim 1,* , Sang Seo Park 3, Mijin Kim 1,4,5, Hyunkwang Lim 1, Ji-Young Kim 6, Dong-Won Lee 6 and Jungho Im 3 1 Department of Atmospheric Sciences, Yonsei University, Seoul 03722, Korea; [email protected] (S.G.); [email protected] (M.K.); [email protected] (H.L.) 2 Joint Center for Earth Systems Technology, University of Maryland Baltimore County, Baltimore, MD 21250, USA 3 School of Urban and Environmental Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Korea; [email protected] (S.S.P.); [email protected] (J.I.) 4 Universities Space Research Association (USRA), Columbia, MD 21046, USA 5 NASA Goddard Space Flight Center (GSFC), Greenbelt, MD 20771, USA 6 National Institute of Environmental Research (NIER), Incheon 22689, Korea; [email protected] (J.-Y.K.); [email protected] (D.-W.L.) * Correspondence: [email protected]; Tel.: +82-2-2123-5682; Fax: +82-2-365-5163 Received: 28 September 2020; Accepted: 1 December 2020; Published: 5 December 2020 Abstract: The retrieval of optimal aerosol datasets by the synergistic use of hyperspectral ultraviolet (UV)–visible and broadband meteorological imager (MI) techniques was investigated. The Aura Ozone Monitoring Instrument (OMI) Level 1B (L1B) was used as a proxy for hyperspectral UV–visible instrument data to which the Geostationary Environment Monitoring Spectrometer (GEMS) aerosol algorithm was applied. Moderate-Resolution Imaging Spectroradiometer (MODIS) L1B and dark target aerosol Level 2 (L2) data were used with a broadband MI to take advantage of the consistent time gap between the MODIS and the OMI. -
Drug Court Practitioner
Drug Court Practitioner February 2016 Fact SheetVol. XI, No. 1 Understanding and Detecting Prescription Drug Misuse and Misuse Disorders By Sandra Lapham, MD, MPH, DFASAM Senior Research Scientist, Behavioral Health Research Center of the Southwest, Pacific Institute for Research and Evaluation his fact sheet is designed for court professionals. It describes prescription T drug misuse and provides information on: • The attributes of the most commonly misused and addictive prescription drugs • The extent and consequences of misuse • Side effects and toxicity • Characteristics of those who are most likely to misuse prescription drugs • Signs and symptoms of misuse • Ways to identify and treat those who may have developed a drug use disorder, including a section on medication-assisted treatment of opioid use disorder • Educational and technical assistance resources on this topic from SAMHSA and other organizations Prescription Drug Misuse drug causes (SAMHSA, 2012). This definition and the Most Commonly covers a wide range of behaviors, from using someone else’s medication to address a Misused Drugs legitimate medical need to misusing prescription The Substance Abuse and Mental Health medications to stay awake, get to sleep, calm Services Administration (SAMHSA) defines down, enhance job or athletic performance, or nonmedical prescription drug misuse as the change one’s mood. use of prescription pain relievers, tranquilizers, People who misuse prescription medications stimulants, sedatives, and other prescription may not understand that, although drugs for drugs in a way other than prescribed, such as treating pain and other medical conditions are for perceived medical need or for the feeling the generally safe when taken as prescribed, they Table 1. -
Resource Guide for Drug Court Applicants
U.S. Department of Justice Office of Justice Programs Bureau of Justice Assistance Drug Court Discretionary Grant Program: FY 2010 Enhancing Adult Drug Court Services, Coordination, and Treatment Solicitation Requirements Resource Guide Table of Contents Introduction ............................................................................................................................................................... 1 About the Requirements Resource Guide .......................................................................................................... 1 Assistance with the Proposal .............................................................................................................................. 1 The Drug Court Movement ................................................................................................................................. 1 Partnership with Treatment ................................................................................................................................. 2 Key Components of Drug Courts........................................................................................................................ 2 General Information................................................................................................................................................... 4 Definitions........................................................................................................................................................... 4 Program Provisions ........................................................................................................................................... -
A Theory of Civil Problem-Solving Courts
GW Law Faculty Publications & Other Works Faculty Scholarship 2018 A Theory of Civil Problem-Solving Courts Jessica K. Steinberg George Washington University Law School, [email protected] Follow this and additional works at: https://scholarship.law.gwu.edu/faculty_publications Part of the Law Commons Recommended Citation Steinberg, Jessica, A Theory of Civil Problem-Solving Courts (2). 93 N.Y.U. L. Rev. (forthcoming 2018); GWU Law School Public Law Research Paper No. 2018-32; GWU Legal Studies Research Paper No. 2018-32. Available at SSRN: https://ssrn.com/abstract=3219306 This Article is brought to you for free and open access by the Faculty Scholarship at Scholarly Commons. It has been accepted for inclusion in GW Law Faculty Publications & Other Works by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. Forthcoming, 93 NYU L. Rev. __ (2018) A THEORY OF CIVIL PROBLEM-SOLVING COURTS JESSICA K. STEINBERG* This Article is the first to develop a problem-solving theory for the civil justice system. Drug courts pioneered the problem-solving model in the 1990s to pursue therapeutic goals as an alternative to “assembly line” jail- based sentencing. This Article explores the potential for migration of the drug court framework into the two most commonly adjudicated private law cases: rental housing and consumer debt. Three structural conditions in the civil courts—systemic lack of counsel, high-volume dockets, and corporate capture of the small claims process—routinely position vulnerable classes of individuals on the losing end of litigation. In the aggregate, these conditions have rendered the civil justice system predictably ineffective in combatting recurring social issues such as substandard housing and unscrupulous debt collection. -
Guideline for Drug Courts on Screening and Assessment
GUIDELINE FOR DRUG COURTS ON SCREENING AND ASSESSMENT Roger H. Peters1 and Elizabeth Peyton2 Prepared for the American University, Justice Programs Office, in association with the U.S. Department of Justice, Office of Justice Programs, Drug Courts Program Office May 1998 1Associate Professor, Department of Mental Health Law and Policy, the Louis de la Parte Florida Mental Health Institute, University of South Florida. 2Executive Director, National TASC — Treatment Accountability for Safer Communities. i ii Acknowledgments The authors express sincere appreciation to the following persons who volunteered their valuable time and expertise to the development of this document: Hon. William G. Meyer Jody Forman Denver Drug Court Project Charlottesville, VA Denver, CO Marc Pearce Hon. Richard S. Gebelein National Association of Drug Delaware Superior Court Court Professionals Wilmington, DE Alexandria, VA Martin O. Conoley Joseph Carloni Santa Barbara County Probation Pathway Treatment Services Santa Barbara, CA Pensacola, FL Ed Brekke Valerie Moore Los Angeles Superior Court IN ACT, Inc. Los Angeles, CA Portland, OR Caroline Cooper The American University Washington, DC iii iv Table of Contents FOREWORD .................................................................................................................. 1 INTRODUCTION .......................................................................................................... 3 What are the differences between screening and assessment? ................................ 3 Goals of screening